PBI News & Analysis
2 articles
Market Mood
Purple Biotech Price Target Cut by H.C. Wainwright
H.C. Wainwright has lowered its price target for Purple Biotech without specifying a new figure. This adjustment comes amid ongoing evaluations of the company’s preclinical progress. While the preclinical results were not detailed, this news reflects the progress of Purple Biotech's development pipeline. A reduction in target price could impact investor sentiment and trading decisions regarding Purple Biotech stock.
Read More: Purple Biotech Price Target Cut by H.C. Wainwright
Pitney Bowes (PBI) CEO Sells 200K Shares for $2.2 Million
Kurt James Wolf, President & CEO of Pitney Bowes (PBI), sold 200,208 common shares for approximately $2.22 million, as reported in an SEC Form 4 filing. This sale accounted for about 2.5% of his total holdings, which now stand at approximately 8,009,831 shares. The shares were sold at a weighted average price of $11.08, aligning with the April 2, 2026 market close of $11.03. For fiscal year 2023, Pitney Bowes reported revenue of $1.89 billion and a net income of $144.70 million.
Read More: Pitney Bowes (PBI) CEO Sells 200K Shares for $2.2 Million